Exploring Best Practices for Screening for Financial Toxicity in Patients With Sarcoma: A Single-Institution Study
- 9 April 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501192
Abstract
PURPOSE: Approximately three quarters of patients with sarcoma report financial toxicity, defined as the psychosocial and economic burden of cancer care. The Comprehensive Score for Financial Toxicity (COST) is a screening questionnaire validated in patients with cancer. However, its use is not widespread in sarcoma care, likely in part due to its complexity. This study aimed to characterize financial toxicity in patients with sarcoma and evaluate whether shorter screening tools can identify high-risk patients. METHODS: We conducted a survey and retrospective cohort study of patients treated for sarcoma at a large, academic sarcoma center in 2016-2024. Patients completed the COST questionnaire (11 graded questions, each scored on a five-point Likert scale from 0 to 4) and the shorter, four-question Worry about Affording Healthcare Scale (WAHS). We obtained clinical information from the electronic health record. We used descriptive statistics to summarize responses to COST, Pearson's correlation coefficient to assess the association between WAHS and COST, and stepwise Spearman correlations to evaluate whether an abbreviated (1-4 question) version of COST correlated highly with total COST score. RESULTS: Among 205 participants, the mean COST score was 20/44 (standard deviation = 6; lower scores indicate greater financial toxicity). Respondents worried most about job loss (mean COST: 0.99) and family finances (mean COST: 1.11). WAHS was weakly correlated with COST (r = 0.47, P < .01). A four-item abbreviated COST tool was strongly correlated with the total COST (ρ = 0.906, P < .0001) and demonstrated high sensitivity (96%) and moderate specificity (75%). CONCLUSION: An abbreviated four-item COST tool could act as a clinically feasible, accurate screening tool after external validation. Routine financial toxicity screening could facilitate timely detection and referral to essential financial navigation resources.Keywords
This publication has 37 references indexed in Scilit:
- Sarcoma Patient Narratives With Respect to the Social Determinants of Health: A Thematic AnalysisPsycho-Oncology, 2025
- Unmet Needs, Quality of Life, and Financial Toxicity Among Survivors of Lung CancerJAMA Network Open, 2024
- The psychological impact of sarcoma on affected patientsPsycho-Oncology, 2023
- Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa studyJournal of Cancer Research and Clinical Oncology, 2023
- Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivorsPsycho-Oncology, 2021
- The unmet needs of carers of patients diagnosed with sarcoma: A qualitative studyPsycho-Oncology, 2021
- Assessing the financial toxicity in Tunisian cancer patients using the Comprehensive Score for Financial Toxicity (COST)Supportive Care in Cancer, 2021
- Experiences of return to work after treatment for extremital soft tissue or bone sarcoma: Between distraction and leaving the disease behindPsycho-Oncology, 2020
- Discrimination and Calibration of Clinical Prediction ModelsJAMA, 2017
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Cancer, 2016